Drugs / Daunorubicin (nonliposomal)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03860844 Background | Aug 2019 → Sep 2022 | acute lymphoblastic leukemia, acute myeloid leukemia | Sanofi | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daunorubicin (nonliposomal) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03860844 ↗ |
| Route | Intravenous | “Route of administration: Intravenous infusion” NCT03860844 ↗ |